Evaluation and management of patients with stage IIIA (N2) non-small-cell lung cancer.
Management of the stage IIIA (N2) patient remains one of the most controversial areas in thoracic oncology. The potential curability of at least some of these patients has encouraged the development of more complex, aggressive, and toxic multimodality treatment regimens.
Garland
L
L
Thoracic Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, Florida, USA.
Robinson
L A
LA
Wagner
H
H
D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology* / Q000628:therapy*; D003131:Combined Modality Therapy; D003952:Diagnostic Imaging; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology* / Q000628:therapy*; D008207:Lymphatic Metastasis; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging